Peptic ulcer disease (PUD), primarily caused by excessive gastric acid secretion, Helicobacter pylori infection, or the use of nonsteroidal anti-inflammatory drugs (NSAIDs), remains a significant global health concern. The pharmacological management of PUD relies on the development of antiulcer drugs that target the underlying mechanisms of ulcer formation and promote mucosal healing. Screening models play a crucial role in the preclinical assessment of potential antiulcer agents, helping to evaluate their efficacy, safety, and mechanisms of action. This review provides a comprehensive overview of the various in vitro and in vivo screening models used for the pharmacological assessment of antiulcer drugs. and high-throughput screening, in advancing drug development is also discussed. This review aims to provide researchers and clinicians with a thorough understanding of the critical role that screening models play in the pharmacological evaluation of antiulcer drugs, highlighti ng both their current applications and future directions in drug development. By improving preclinical testing, more effective and safer antiulcer therapies can be developed forthe management of peptic ulcer disease.